Recent studies based on TCGA analysis revealed that, in human colon cancer specimens, a stronger activity of β-catenin/TCF responsive promoter was associated with a higher transcription of IGF2 and IGF1R, which can be important in design of therapies employing IGF1R/IR inhibitors [150]. This evidence concerns the gene IGF1R and colonic neoplasm.